Back Login to subscribe 🔔 Set Alert

BNTX BioNTech SE American Depositary Share

Sector: Healthcare

Industry: Biotechnology

15 min delay

Today's News Sentiment

Loading...

Upcoming Earnings

Loading...

BNTX Fundamental Data

Loading...

Similar Companies

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

BNTX Insider Transactions

Loading insider data…

BNTX News

Date	Headline	Sentiment
	Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132	69.58%
	Why Is BioNTech Stock Falling Tuesday?	59.04%
	BioNTech shares are trading lower after the company announced its Phase 2/3 trial of BNT113 failed to meet a key progression-free survival endpoint in HPV16-positive head and neck cancer.	97.07%
	BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone	60.27%
	A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally	92.57%
	Shares of vaccine stocks are trading higher following a New York Times report detailing a new public-private partnership involving the National Institutes of Health to accelerate cancer vaccine development.	88.15%
	Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times	93.5%
	Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114	92.09%
	Reported Earlier: 'BioNTech to shutter three sites in Germany as no buyers emerge' - Reuters	83.75%